KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.J Allergy Clin Immunol PractPMID 34848381无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.Br J Clin PharmacolPMID 35029306PMC93026932022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.AllergyPMID 35034364PMC93052282022-Jul0.98未发现恶性肿瘤人群证据。待处理
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.Br J Clin PharmacolPMID 35072287PMC93054662022-Jul0.98未发现恶性肿瘤人群证据。待处理
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.J Diabetes InvestigPMID 35199478PMC92484262022-Jul0.98未发现恶性肿瘤人群证据。待处理
Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.Eur J NeurolPMID 35258154无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.J Eur Acad Dermatol VenereolPMID 35297108无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.Eur J NeurolPMID 35302681无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes.Diabetes Obes MetabPMID 35322535无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.J Gastroenterol HepatolPMID 35342997无 PMCID2022-Jul0.95Study is not oncology-related; it investigates duodenal ulcer healing and H. pylori eradication, not a malignant neoplasm. No time-to-event efficacy endpoint is present.待处理
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.Gastric CancerPMID 35352176无 PMCID2022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.Lancet Respir MedPMID 35364018无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Gastroenterol HepatolPMID 35366419无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.Ann OncolPMID 35395383无 PMCID2022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.J Allergy Clin Immunol PractPMID 35398549无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.J RheumatolPMID 35428720无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.Clin Oncol (R Coll Radiol)PMID 35466013无 PMCID2022-Jul0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial.Am J HematolPMID 35472008PMC93253772022-Jul0.98未发现恶性肿瘤人群证据。待处理
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.HaemophiliaPMID 35475308PMC95429082022-Jul0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.Br J HaematolPMID 35476316PMC95412432022-Jul0.85The record describes a secondary analysis of a Phase 3, randomized trial (JAKARTA) and a Phase 2 trial (JAKARTA2) evaluating fedratinib in myelofibrosis. While it meets criteria for oncology, human, randomized, phase 3, and drug intervention, it does not meet the time-to-event efficacy endpoint criterion. The abstract reports only categorical response rates (spleen and symptom response) at a fixed timepoint, with no mention of time-to-event outcomes like OS, PFS, or Kaplan-Meier analyses. Additionally, the report itself is a subgroup analysis (low-platelet patients), not the primary trial report. Therefore, it is ineligible.待处理
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.Lancet NeurolPMID 35483387无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).Eur J CancerPMID 35489301无 PMCID2022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.Radiother OncolPMID 35513132无 PMCID2022-Jul0.45While the record is from a Phase III randomized oncology trial, the abstract does not report any survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for eligibility. It is a technical planning quality assurance study.待处理
Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.Korean J Intern MedPMID 35526858PMC92717232022-Jul0.98未发现恶性肿瘤人群证据。待处理
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.Eur J CancerPMID 35569283无 PMCID2022-Jul1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.Lancet HaematolPMID 35597252无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.Clin Lung CancerPMID 35613998PMC96348572022-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.Ann HematolPMID 35643952无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.Lung CancerPMID 35660972无 PMCID2022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.Lancet OncolPMID 35688173PMC103050872022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.Lancet OncolPMID 35690073PMC96301602022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.Paediatr DrugsPMID 35698000PMC92058112022-Jul0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.Lancet NeurolPMID 35716692无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.Am J Clin DermatolPMID 35857179PMC93344312022-Jul0.98未发现恶性肿瘤人群证据。待处理
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.NEJM EvidPMID 38319255无 PMCID2022-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.Arthritis Res TherPMID 35773713PMC92452322022-Jun-300.98未发现恶性肿瘤人群证据。待处理
Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.Nephrol Dial TransplantPMID 34240198PMC92176502022-Jun-230.98未发现恶性肿瘤人群证据。待处理
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.Antimicrob Agents ChemotherPMID 35502922PMC92114362022-Jun-210.98未发现恶性肿瘤人群证据。待处理
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.J Clin OncolPMID 35230884PMC91973532022-Jun-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.J Clin OncolPMID 35316080无 PMCID2022-Jun-201.00命中用户提供的消化道肿瘤阳性参考集。待处理
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.LancetPMID 35717989无 PMCID2022-Jun-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.J Clin Endocrinol MetabPMID 35325149PMC92027232022-Jun-160.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol MetabPMID 35405011PMC92027172022-Jun-160.98未发现恶性肿瘤人群证据。待处理
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.N Engl J MedPMID 35704479PMC97176772022-Jun-160.95The record is a Phase III randomized trial with a time-to-event endpoint for a human oncology condition (anal cancer). However, it is ineligible because the intervention is not a drug-containing regimen for treating an established malignant neoplasm; it is a prevention trial using procedural and topical interventions for precancerous lesions.待处理
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.Blood AdvPMID 35143644PMC91989082022-Jun-140.55The trial is a Phase III randomized controlled trial in oncology (hematological malignancy) with time-to-event endpoints (GRFS, OS, PFS) and reports original results. However, the core intervention is a post-transplant immunosuppressive regimen (cyclophosphamide, cyclosporine, mycophenolic acid) for GVHD prevention, not a primary antineoplastic drug therapy for the malignancy itself. The review criteria require a 'drug-containing intervention' for the malignancy. This study is ambiguous on whether the immunosuppressive drugs are considered the 'drug intervention' in the oncologic sense required for eligibility. Therefore, cannot definitively set is_eligible to true without clarifying this specific criterion.待处理
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.SleepPMID 34358324PMC91899762022-Jun-130.98未发现恶性肿瘤人群证据。待处理
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.Clin Cancer ResPMID 35275197PMC92975292022-Jun-130.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities.J Neurodev DisordPMID 35690720PMC91881392022-Jun-110.98未发现恶性肿瘤人群证据。待处理
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.LancetPMID 35691323无 PMCID2022-Jun-110.98未发现恶性肿瘤人群证据。待处理
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).Clin Infect DisPMID 34467969PMC91873272022-Jun-100.98未发现恶性肿瘤人群证据。待处理